Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Files An 8-K Financial Statements and ExhibitsItem 9.01
(d)Exhibits.
|
Exhibit No. |
Description |
| 1.1 | Underwriting Agreement, dated July 19, 2017, by and among Inovio Pharmaceuticals, Inc. and Citigroup Global Markets Inc. and Piper Jaffray & Co., as representatives of the several underwriters named therein |
| 5.1 | Opinion of Cooley LLP |
| 23.1 | Consent of Cooley LLP (included in Exhibit 5.1) |
| 99.1 | Press Release, dated July 18, 2017, titled “Inovio Announces Proposed Public Offering of Common Stock” |
| 99.2 | Press Release, dated July 19, 2017, titled “Inovio Announces Pricing of Public Offering of Common Stock” |
INOVIO PHARMACEUTICALS, INC. ExhibitEX-1.1 2 d429850dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 EXECUTION VERSION 12,…To view the full exhibit click here
About Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Inovio Pharmaceuticals, Inc. (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses.
